Post hoc analysis of SURMOUNT-1 (392 adults with obesity analysed): at 72 weeks tirzepatide 5–15 mg vs placebo was associated with lower hsCRP (−36.9% to −54.6%), IL-6, leptin, HOMA-IR, E-selectin and PAI-1 and higher adiponectin; no consistent change in fibrinogen.
Secondary analysisn = 392
Sattar et al. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis